flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 Long-term of in obesity and cardiovascular disease in the SELECT FLOWing with the SemagluTIDE —

Preliminary evidence suggests liraglutide use in type 1 diabetes benefits glycaemic control, glucose variability, reduced dosage of insulin and body weight

April 22 Product: ImmunityBios Anktiva Indication: Non-muscle invasive bladder cancer A large number of bladder cancer patients will have a new treatment option as the FDA on Monday greenlit ImmunityBios Anktiva, a first-in-class IL-15 superagonist for non-muscle invasive bladder cancerwhich accounts for approximately 80% of new cases, according to the company

Volume: 3mL

Author Contributions Aleksandrina Ruseva, Wojciech Michalak, Anthony Fabricatore, Brain Hartaigh, and Zhenxiang Zhao were responsible for the study concept and design, data interpretation and analysis, drafting/revising the manuscript, and reviewing/approving the final version for submission